BCRX
Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
CUSIP: 09058V103HealthcareUS1 holder
Total Value
$4.91M
Total Shares
491.1K
Net Share Change
-147.0K
Activity
1 selling
Investor
Value
Shares
Weight
Change
